journal article·2017Open access

Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery Systems

Susanne R. Youngren-Ortiz, Nishant S. Gandhi, Laura España-Serrano, Mahavir B. Chougule

KONA Powder and Particle Journal· Volume 34· Issue 0

Abstract

In this article, applications of engineered nanoparticles containing siRNA for inhalation delivery are reviewed and discussed. Diseases with identified protein malfunctions may be mitigated through the use of well-designed siRNA therapeutics. The inhalation route of administration provides local delivery of siRNA therapeutics to the lungs for various pulmonary diseases. A siRNA delivery system can be used to overcome the barriers of pulmonary delivery, such as anatomical barriers, mucociliary clearance, cough clearance, and alveolar macrophage clearance. Apart from naked siRNA aerosol delivery, previously studied siRNA carrier systems include those of lipidic, polymeric, peptide, or inorganic origin. These delivery systems can achieve pulmonary delivery through the generation of an aerosol via an inhaler or nebulizer. The preparation methodologies for these siRNA nanocarrier systems will be discussed herein. The use of inhalable nanocarrier siRNA delivery systems have barriers to their effective delivery, but overcoming these constraints while formulating a safe and effective delivery system will offer unique advances to the field of inhaled medicine.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanopore and Nanochannel Transport Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Translational Drug Delivery Research (TransDDR) Laboratory, Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, USA

Natural Products and Experimental Therapeutics Program, The Cancer Research Center, University of Hawaii at Manoa, USA

Funding

National Institute of General Medical Sciences · Hawai’i Community Foundation · Research Corporation of the University of Hawai‘i · The Daniel K. Inouye College of Pharmacy, University of Hawai‘i at Hilo

References (100+)

Show source-provided references
1. Aalto A.P., Sarin L.P., Van Dijk A.A., Saarma M., Poranen M.M., Arumae U. and Bamford D.H., Large-scale production of dsRNA and siRNA pools for RNA interference utilizing bacteriophage phi6 RNA-dependent RNA polymerase, RNA, 13 (2007) 422–429.10.1261/rna.348307 ↗
2. Aboubakar M., Puisieux F., Couvreur P., Deyme M. and Vauthier C., Study of the mechanism of insulin encapsulation in poly (isobutylcyanoacrylate) nanocapsules obtained by interfacial polymerization, Journal of biomedical materials research, 47 (1999) 568–576.10.1002/(SICI)1097-4636(19991215)47:4<568::AID-JBM14>3.0.CO;2-X ↗
3. Akinc A., Zumbuehl A., Goldberg M., Leshchiner E.S., Busini V., Hossain N., Bacallado S.A., Nguyen D.N., Fuller J. and Alvarez R., A combinatorial library of lipid-like materials for delivery of RNAi therapeutics, Nature biotechnology, 26 (2008) 561–569.10.1038/nbt1402 ↗
4. Allison S.D. and Anchordoquy T.J., Mechanisms of protection of cationic lipid DNA complexes during lyophilization, Journal of pharmaceutical sciences, 89 (2000) 682–691.10.1002/(SICI)1520-6017(200005)89:5<682::AID-JPS14>3.0.CO;2-# ↗
5. Allison S.D. and Anchordoquy T.J., Maintenance of nonviral vector particle size during the freezing step of the lyophilization process is insufficient for preservation of activity: Insight from other structural indicators, Journal of pharmaceutical sciences, 90 (2001) 1445–1455.10.1002/jps.1096 ↗
6. Allison S.D., Dc Molina M. and Anchordoquy T.J., Stabilization of lipid/DNA complexes during the freezing step of the lyophilization process: The particle isolation hypothesis, Biochimica et Biophysica Acta (BBA)-Biomembranes, 1468 (2000) 127–138.10.1016/S0005-2736(00)00251-0 ↗
7. Alvarez R., Elbashir S., Borland T., Toudjarska I., Hadwiger P., John M., Roehl I., Morskaya S.S., Martinello R., Kahn J., Van Ranst M., Tripp R.A., Devincenzo J.P., Pandey R., Maier M., Nechev L., Manoharan M., Kotelianski V. and Meyers R., RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy, Antimicrob Agents Chemother, 53 (2009) 3952–3962.10.1128/AAC.00014-09 ↗
8. Amarzguioui M., Rossi J.J. and Kim D., Approaches for chemically synthesized siRNA and vector-mediated RNAi, FEBS Letters, 579 (2005) 5974–5981.10.1016/j.febslet.2005.08.070 ↗
9. Anchordoquy T.J., Carpenter J.F. and Kroll D.J., Maintenance of transfection rates and physical characterization of lipid/DNA complexes after freeze-drying and rehydration, Archives of biochemistry and biophysics, 348 (1997) 199–206.10.1006/abbi.1997.0385 ↗
10. Arias J., Gallardo V., Gomez-Lopera S., Plaza R. and Delgado A., Synthesis and characterization of poly (ethyl-2-cyanoacrylate) nanoparticles with a magnetic core, Journal of Controlled Release, 77 (2001) 309–321.10.1016/S0168-3659(01)00519-3 ↗
11. Baoum A., Ovcharenko D. and Berkland C., Calcium condensed cell penetrating peptide complexes offer highly efficient, low toxicity gene silencing, Int J Pharm, 427 (2012) 134–142.10.1016/j.ijpharm.2011.08.012 ↗
12. Barichello J.M., Morishita M., Takayama K. and Nagai T., Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method, Drug development and industrial pharmacy, 25 (1999) 471–476.10.1081/DDC-100102197 ↗
13. Benfer M. and Kissel T., Cellular uptake mechanism and knockdown activity of siRNA-loaded biodegradable DEAPA-PVA-g-PLGA nanoparticles, European Journal of Pharmaceutics and Biopharmaceutics, 80 (2012) 247–256.10.1016/j.ejpb.2011.10.021 ↗
14. Biswas S., Knipp R.J., Gordon L.E., Nandula S.R., Gorr S.U., Clark G.J. and Nantz M.H., Hydrophobic oxime ethers: A versatile class of pDNA and siRNA transfection lipids, ChemMedChem, 6 (2011) 2063–2069.10.1002/cmdc.201100259 ↗
15. Bitko V., Musiyenko A., Shulyayeva O. and Barik S., Inhibition of respiratory viruses by nasally administered siRNA, Nature medicine, 11 (2005) 50–55.10.1038/nm1164 ↗
16. Blasig A., Shi C., Enick R.M. and Thies M.C., Effect of concentration and degree of saturation on RESS of a CO2-soluble fluoropolymer, Industrial & engineering chemistry research, 41 (2002) 4976–4983.10.1021/ie0201819 ↗
17. Bochicchio S., Dalmoro A., Barba A.A., Grassi G. and Lamberti G., Liposomes as siRNA delivery vectors, Current drug metabolism, 15 (2014) 882–892.10.2174/1389200216666150206124913 ↗
18. Borm P., Klaessig F.C., Landry T.D., Moudgil B., Pauluhn J., Thomas K., Trottier R. and Wood S., Research strategies for safety evaluation of nanomaterials, part V: Role of dissolution in biological fate and effects of nanoscale particles, Toxicol Sci, 90 (2006) 23–32.10.1093/toxsci/kfj084 ↗
19. Braunecker W.A. and Matyjaszewski K., Controlled/living radical polymerization: Features, developments, and perspectives, Progress in Polymer Science, 32 (2007) 93–146.10.1016/j.progpolymsci.2006.11.002 ↗
20. Burnett J.C. and Rossi J.J., RNA-based therapeutics: Current progress and future prospects, Chemistry & biology, 19 (2012) 60–71.10.1016/j.chembiol.2011.12.008 ↗
21. Burnett J.C., Rossi J.J. and Tiemann K., Current progress of siRNA/shRNA therapeutics in clinical trials, Biotechnology Journal, 6 (2011) 1130–1146.10.1002/biot.201100054 ↗
22. Buyens K., Demeester J., De Smedt S.S. and Sanders N.N., Elucidating the encapsulation of short interfering RNA in pegylated cationic liposomes, Langmuir, 25 (2009) 4886–4891.10.1021/la803973p ↗
23. Çağdaş M., Sezer A.D. and Bucak S., Liposomes as potential drug carrier systems for drug delivery, 2014.10.5772/58459 ↗
24. Calvo P., Remuñan-López C., Vila-Jato J.L. and Alonso M.J., Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines, Pharmaceutical Research, 14 (1997a) 1431–1436.10.1023/A:1012128907225 ↗
25. Calvo P., Remunan Lopez C., Vila Jato J. and Alonso M., Novel hydrophilic chitosan polyethylene oxide nanoparticles as protein carriers, Journal of Applied Polymer Science, 63 (1997b) 125–132.10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4 ↗
26. Cao W., De Oliveira Ribeiro R., Liu D., Saintigny P., Xia R., Xue Y., Lin R., Mao L. and Ren H., EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer, PloS one, 7 (2012) e52984.10.1371/journal.pone.0052984 ↗
27. Caplen N.J., Alton E.W., Mddleton P.G., Dorin J.R., Stevenson B.J., Gao X., Durham S.R., Jeffery P.K., Hodson M.E. and Coutelle C., Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis, Nature medicine, 1 (1995) 39–46.10.1038/nm0195-39 ↗
28. Carmona S., Jorgensen M.R., Kolli S., Crowther C., Salazar F.H., Marion P.L., Fujino M., Natori Y., Thanou M. and Arbuthnot P., Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles, Molecular pharmaceutics, 6 (2009) 706–717.10.1021/mp800157x ↗
29. Cavalli R., Caputo O., Carlotti M.E., Trotta M., Scarnecchia C. and Gasco M.R., Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles, International journal of pharmaceutics, 148 (1997) 47–54.10.1016/S0378-5173(96)04822-3 ↗
30. Chen A.M., Zhang M., Wei D., Stueber D., Taratula O., Minko T. and He H., Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells, Small, 5 (2009) 2673–2677.10.1002/smll.200900621 ↗
31. Chen G., Kronenberger P., Teugels E., Umelo I.A. and De Grève J., Targeting the epidermal growth factor receptor in nonsmall cell lung cancer cells: The effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab, BMC medicine, 10 (2012) 28.10.1186/1741-7015-10-28 ↗
32. Chen S., Ni B., Huang H., Chen X. and Ma H., siRNA-loaded pegylated porous silicon nanoparticles for lung cancer therapy, Journal of Nanoparticle Research, 16 (2014) 1–8.
33. Chernyak Y., Henon F., Harris R.B., Gould R.D., Franklin R.K., Edwards J.R., Desimone J.M. and Carbonell R.G., Formation of perfluoropolyether coatings by the rapid expansion of supercritical solutions (RESS) process. Part 1: Experimental results, Industrial & engineering chemistry research, 40 (2001) 6118–6126.10.1021/ie010267m ↗
34. Choi M., Lee M. and Rhim T., Dexamethasone-conjugated polyethylenimine/mif siRNA complex regulation of particulate matter-induced airway inflammation, Biomaterials, 34 (2013) 7453–7461.10.1016/j.biomaterials.2013.05.082 ↗
35. Chougule M., Padhi B. and Misra A., Nano-liposomal dry powder inhaler of tacrolimus: Preparation, characterization, and pulmonary pharmacokinetics, Int J Nanomedicine, 2 (2007) 675–688.
36. Chougule M., Padhi B. and Misra A., Development of spray dried liposomal dry powder inhaler of dapsone, AAPS PharmSciTech, 9 (2008) 47–53.10.1208/s12249-007-9024-6 ↗
37. Clark K.L., Hughes S.A., Bulsara P., Coates J., Moores K., Parry J., Carr M., Mayer R.J., Wilson P. and Gruenloh C., Pharmacological characterization of a novel ENaCα siRNA (GSK2225745) with potential for the treatment of cystic fibrosis, Molecular Therapy—Nucleic Acids, 2 (2013) e65.10.1038/mtna.2012.57 ↗
38. Corey D.R., Synthesis of oligonucleotide-peptide and oligonucleotide-protein conjugates, (Eds), Bioconjugation protocols, Springer, 2004, pp. 197–206.10.1385/1-59259-813-7:197 ↗
39. Crespy D., Stark M., Hoffmann-Richter C., Ziener U. and Landfester K., Polymeric nanoreactors for hydrophilic reagents synthesized by interfacial polycondensation on miniemulsion droplets, Macromolecules, 40 (2007) 3122–3135.10.1021/ma0621932 ↗
40. Crowe J.H. and Crowe L.M., Factors affecting the stability of dry liposomes, Biochimica et Biophysica Acta (BBA)-Biomembranes, 939 (1988) 327–334.10.1016/0005-2736(88)90077-6 ↗
41. D’alessandro-Gabazza C.N., Kobayashi T., Boveda-Ruiz D., Takagi T., Toda M., Gil-Bernabe P., Miyake Y., Yasukawa A., Matsuda Y. and Suzuki N., Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis, American journal of respiratory cell and molecular biology, 46 (2012) 397–406.10.1165/rcmb.2011-0158OC ↗
42. Danicher L., Frère Y. and Le Calvé A., Synthesis by interfacial polycondensation of polyamide capsules with various sizes. Characteristics and properties, Macromolecular Symposia, Wiley Online Library, 2000.10.1002/1521-3900(200002)151:1<387::AID-MASY387>3.0.CO;2-D ↗
43. De Backer L., Cerrada A., Pérez-Gil J., De Smedt S.C. and Raemdonck K., Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy, Journal of Controlled Release, (2015).10.1016/j.jconrel.2015.09.004 ↗
44. De Fougerolles A. and Novobrantseva T., siRNA and the lung: Research tool or therapeutic drug?, Curr Opin Pharmacol, 8 (2008) 280–285.10.1016/j.coph.2008.04.005 ↗
45. De Fougerolles A.R., Delivery vehicles for small interfering RNA in vivo, Human gene therapy, 19 (2008) 125–132.10.1089/hum.2008.928 ↗
46. Deshayes S., Morris M., Divita G. and Heitz F., Cell-penetrating peptides: Tools for intracellular delivery of therapeutics, Cellular and Molecular Life Sciences CMLS, 62 (2005) 1839–1849.10.1007/s00018-005-5109-0 ↗
47. Devincenzo J., Cehelsky J.E., Alvarez R., Elbashir S., Harborth J., Toudjarska I., Nechev L., Murugaiah V., Van Vliet A. and Vaishnaw A.K., Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV), Antiviral research, 77 (2008) 225–231.10.1016/j.antiviral.2007.11.009 ↗
48. Devincenzo J., Lambkin-Williams R., Wilkinson T., Cehelsky J., Nochur S., Walsh E., Meyers R., Gollob J. and Vaishnaw A., A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus, Proceedings of the National Academy of Sciences, 107 (2010) 8800–8805.10.1073/pnas.0912186107 ↗
49. Devincenzo J.P., Harnessing RNA interference to develop neonatal therapies: From nobel prize winning discovery to proof of concept clinical trials, Early Hum Dev, 85 (2009) S31–35.10.1016/j.earlhumdev.2009.08.013 ↗
50. Dire C., Magnet S., Couvreur L. and Charleux B., Nitroxide-mediated controlled/living free-radical surfactant-free emulsion polymerization of methyl methacrylate using a poly (methacrylic acid)-based macroalkoxyamine initiator, Macromolecules, 42 (2008) 95–103.10.1021/ma802083g ↗
51. Dokka S., Toledo D., Shi X., Castranova V. and Rojanasakul Y., Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes, Pharmaceutical research, 17 (2000) 521–525.10.1023/A:1007504613351 ↗
52. Dustgania A., Vasheghani Farahani E. and Imani M., Preparation of chitosan nanoparticles loaded by dexamethasone sodium phosphate, Iranian Journal of Pharmaceutical Sciences, 4 (2008) 111–114.
53. Eliyahu H., Siani S., Azzam T., Domb A.J. and Barenholz Y., Relationships between chemical composition, physical properties and transfection efficiency of polysaccharide–spermine conjugates, Biomaterials, 27 (2006) 1646–1655.10.1016/j.biomaterials.2005.09.005 ↗
54. Endoh T. and Ohtsuki T., Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape, Advanced drug delivery reviews, 61 (2009) 704–709.10.1016/j.addr.2009.04.005 ↗
55. Fallouh N.a.K., Roblot-Treupel L., Fessi H., Devissaguet J.P. and Puisieux F., Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules, International Journal of Pharmaceutics, 28 (1986) 125–132.10.1016/0378-5173(86)90236-X ↗
56. Felgner P.L., Tsai Y.J., Sukhu L., Wheeler C.J., Manthorpe M., Marshall J. and Cheng S.H., Improved cationic lipid formulations for in vivo gene therapy, Annals of the New York Academy of Sciences, 772 (1995) 126–139.10.1111/j.1749-6632.1995.tb44738.x ↗
57. Fellmann C. and Lowe S.W., Stable RNA interference rules for silencing, Nature cell biology, 16 (2014) 10–18.10.1038/ncb2895 ↗
58. Fessi H., Puisieux F., Devissaguet J.P., Ammoury N. and Benita S., Nanocapsule formation by interfacial polymer deposition following solvent displacement, International journal of pharmaceutics, 55 (1989) R1–R4.10.1016/0378-5173(89)90281-0 ↗
59. Finnie K.S., Waller D.J., Perret F.L., Krause-Heuer A.M., Lin H.Q., Hanna J.V. and Barbé C.J., Biodegradability of sol–gel silica microparticles for drug delivery, Journal of Sol-Gel Science and Technology, 49 (2008) 12–18.10.1007/s10971-008-1847-4 ↗
60. Fire A., Xu S.Q., Montgomery M.K., Kostas S.A., Driver S.E. and Mello C.C., Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans, Nature, 391 (1998) 806–811.10.1038/35888 ↗
61. Fourtounis J., Wang I.-M., Mathieu M.-C., Claveau D., Loo T., Jackson A.L., Peters M.A., Therien A.G., Boie Y. and Crackower M.A., Gene expression profiling following NRF2 and KEAP1 siRNA knockdown in human lung fibroblasts identifies CCL11/Eotaxin-1 as a novel NRF2 regulated gene, Respir Res, 13 (2012) 92.10.1186/1465-9921-13-92 ↗
62. Galindo-Rodriguez S., Allemann E., Fessi H. and Doelker E., Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods, Pharmaceutical research, 21 (2004) 1428–1439.10.1023/B:PHAM.0000036917.75634.be ↗
63. Gallardo M., Couarraze G., Denizot B., Treupel L., Couvreur P. and Puisieux F., Study of the mechanisms of formation of nanoparticles and nanocapsules of polyisobutyl-2-cyanoacrylate, International journal of pharmaceutics, 100 (1993) 55–64.10.1016/0378-5173(93)90075-Q ↗
64. Ganachaud F. and Katz J.L., Nanoparticles and nanocapsules created using the ouzo effect: Spontaneous emulsification as an alternative to ultrasonic and high shear devices, ChemPhysChem, 6 (2005) 209–216.10.1002/cphc.200400527 ↗
65. Gandhi N.S., Tekade R.K. and Chougule M.B., Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances, J Control Release, 194 (2014) 238–256.10.1016/j.jconrel.2014.09.001 ↗
66. Gao X. and Huang L., Potentiation of cationic liposome-mediated gene delivery by polycations, Biochemistry, 35 (1996) 1027–1036.10.1021/bi952436a ↗
67. Garbuzenko O.B., Saad M., Pozharov V.P., Reuhl K.R., Mainelis G. and Minko T., Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance, Proceedings of the National Academy of Sciences of the United States of America, 107 (2010) 10737–10742.10.1073/pnas.1004604107 ↗
68. Gasco M. and Trotta M., Nanoparticles from microemulsions, International journal of pharmaceutics, 29 (1986) 267–268.10.1016/0378-5173(86)90125-0 ↗
69. Gaspar M.M., Bakowsky U. and Ehrhardt C., Inhaled liposomes–current strategies and future challenges, Journal of Biomedical Nanotechnology, 4 (2008) 245–257.10.1166/jbn.2008.334 ↗
70. Gaudin F. and Sintes-Zydowicz N., Core–shell biocompatible polyurethane nanocapsules obtained by interfacial step polymerisation in miniemulsion, Colloids and Surfaces A: Physicochemical and Engineering Aspects, 331 (2008) 133–142.10.1016/j.colsurfa.2008.07.028 ↗
71. Glasgow M.D. and Chougule M.B., Recent developments in active tumor targeted multifunctional nanoparticles for combination chemotherapy in cancer treatment and imaging, Journal of Biomedical Nanotechnology, 11 (2015) 1859–1898.10.1166/jbn.2015.2145 ↗
72. Gutbier B., Kube S.M., Reppe K., Santel A., Lange C., Kaufmann J., Suttorp N. and Witzenrath M., RNAi-mediated suppression of constitutive pulmonary gene expression by small interfering RNA in mice, Pulmonary pharmacology & therapeutics, 23 (2010) 334–344.10.1016/j.pupt.2010.03.007 ↗
73. Ham H.T., Choi Y.S., Chee M.G. and Chung I.J., Singlewall carbon nanotubes covered with polystyrene nanoparticles by in situ miniemulsion polymerization, Journal of Polymer Science Part A: Polymer Chemistry, 44 (2006) 573–584.10.1002/pola.21185 ↗
74. Hamasaki T., Suzuki H., Shirohzu H., Matsumoto T., D’alessandro-Gabazza C.N., Gil-Bernabe P., Boveda-Ruiz D., Naito M., Kobayashi T. and Toda M., Efficacy of a novel class of RNA interference therapeutic agents, PloS one, 7 (2012) e42655.10.1371/journal.pone.0042655 ↗
75. Hannon G.J., RNA interference, Nature, 418 (2002) 244–251.10.1038/418244a ↗
76. Heidel J.D., Liu J.Y.-C., Yen Y., Zhou B., Heale B.S., Rossi J.J., Bartlett D.W. and Davis M.E., Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo, Clinical Cancer Research, 13 (2007) 2207–2215.10.1158/1078-0432.CCR-06-2218 ↗
77. Hermanson G.T., Bioconjugate techniques, Academic press, 2013.
78. Hofland H., Shephard L. and Sullivan S.M., Formation of stable cationic lipid/DNA complexes for gene transfer, Proceedings of the National Academy of Sciences, 93 (1996) 7305–7309.10.1073/pnas.93.14.7305 ↗
79. Hong K., Zheng W., Baker A. and Papahadjopoulos D., Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly (ethylene glycol)-phospholipid conjugates for efficient in vivo gene delivery, FEBS letters, 400 (1997) 233–237.10.1016/S0014-5793(96)01397-X ↗
80. Hong S.-H., Kim J.-E., Kim Y.-K., Minai-Tehrani A., Shin J.-Y., Kang B., Kim H.-J., Cho C.-S., Chae C. and Jiang H.-L., Suppression of lung cancer progression by biocompatible glycerol triacrylate–spermine-mediated delivery of shakt1, International journal of nanomedicine, 7 (2012) 2293.
81. Hong S.-H., Minai-Tehrani A., Chang S.-H., Jiang H.-L., Lee S., Lee A.-Y., Seo H.W., Chae C., Beck Jr G.R. and Cho M.-H., Knockdown of the sodium-dependent phosphate co-transporter 2b (NPT2b) suppresses lung tumorigenesis, PloS one, 8 (2013) e77121.10.1371/journal.pone.0077121 ↗
82. Huang B., Zhou H., Wang X. and Liu Z., Silencing satb1 with siRNA inhibits the proliferation and invasion of small cell lung cancer cells, Cancer Cell Int, 13 (2013).10.1186/1475-2867-13-8 ↗
83. Innes A.L., Carrington S.D., Thornton D.J., Kirkham S., Rousseau K., Dougherty R.H., Raymond W.W., Caughey G.H., Muller S.J. and Fahy J.V., ex vivo sputum analysis reveals impairment of protease-dependent mucus degradation by plasma proteins in acute asthma, American journal of respiratory and critical care medicine, 180 (2009) 203–210.10.1164/rccm.200807-1056OC ↗
84. Jensen D.K., Jensen L.B., Koocheki S., Bengtson L., Cun D., Nielsen H.M. and Foged C., Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA, J Control Release, 157 (2012) 141–148.10.1016/j.jconrel.2011.08.011 ↗
85. Jensen D.M., Cun D., Maltesen M.J., Frokjaer S., Nielsen H.M. and Foged C., Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation, J Control Release, 142 (2010) 138–145.10.1016/j.jconrel.2009.10.010 ↗
86. Jeong J.H., Mok H., Oh Y.-K. and Park T.G., siRNA conjugate delivery systems, Bioconjugate chemistry, 20 (2008) 5–14.10.1021/bc800278e ↗
87. Jiang H.L., Lim H.T., Kim Y.K., Arote R., Shin J.Y., Kwon J.T., Kim J.E., Kim J.H., Kim D., Chae C., Nah J.W., Choi Y.J., Cho C.S. and Cho M.H., Chitosan-graft-spermine as a gene carrier in vitro and in vivo, Eur J Pharm Biopharm, 77 (2011) 36–42.10.1016/j.ejpb.2010.09.014 ↗
88. Jung T., Kamm W., Breitenbach A., Kaiserling E., Xiao J. and Kissel T., Biodegradable nanoparticles for oral delivery of peptides: Is there a role for polymers to affect mucosal uptake?, European Journal of Pharmaceutics and Biopharmaceutics, 50 (2000) 147–160.10.1016/S0939-6411(00)00084-9 ↗
89. Kalariya M., Padhi B.K., Chougule M. and Misra A., Clobetasol propionate solid lipid nanoparticles cream for effective treatment of eczema: Formulation and clinical implications, Indian J Exp Biol, 43 (2005) 233–240.
90. Kanasty R., Dorkin J.R., Vegas A. and Anderson D., Delivery materials for siRNA therapeutics, Nature materials, 12 (2013) 967–977.10.1038/nmat3765 ↗
91. Karode S., Kulkarni S., Suresh A. and Mashelkar R., New insights into kinetics and thermodynamics of interfacial polymerization, Chemical engineering science, 53 (1998) 2649–2663.10.1016/S0009-2509(98)00083-9 ↗
92. Kasper J.C., Schaffert D., Ogris M., Wagner E. and Friess W., Development of a lyophilized plasmid/LPEI polyplex formulation with long-term stability—a step closer from promising technology to application, Journal of Controlled Release, 151 (2011) 246–255.10.1016/j.jconrel.2011.01.003 ↗
93. Kawashima Y., Nanoparticulate systems for improved drug delivery, Advanced drug delivery reviews, 47 (2001) 1–2.10.1016/S0169-409X(00)00117-4 ↗
94. Keefe D., Agency response letter GRAS notice no. GRN 000397, 2011, FDA (U.S. Food and Drug Administration) accessed 29.02.2016.
95. Kim D.H. and Rossi J.J., Strategies for silencing human disease using RNA interference, Nature Reviews Genetics, 8 (2007) 173–184.10.1038/nrg2006 ↗
96. Kim S.S., Peer D., Kumar P., Subramanya S., Wu H., Asthana D., Habiro K., Yang Y.G., Manjunath N., Shimaoka M. and Shankar P., RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice, Mol Ther, 18 (2010) 370–376.10.1038/mt.2009.271 ↗
97. Kostag M., Köhler S., Liebert T. and Heinze T., Pure cellulose nanoparticles from trimethylsilyl cellulose, Macromolecular symposia, Wiley Online Library, 2010.10.1002/masy.200900095 ↗
98. Kostarelos K. and Miller A.D., Synthetic, self-assembly ABCD nanoparticles; a structural paradigm for viable synthetic non-viral vectors, Chemical Society Reviews, 34 (2005) 970–994.10.1039/b307062j ↗
99. Kreuter J., On the mechanism of termination in heterogeneous polymerization, Journal of Polymer Science: Polymer Letters Edition, 20 (1982) 543–545.10.1002/pol.1982.130201006 ↗
100. Krützfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M. and Stoffel M., Silencing of microRNAs in vivo with ‘antagomirs’, nature, 438 (2005) 685–689.10.1038/nature04303 ↗